The global liquid biopsy market is anticipated to value over US$ 8.4 billion by the
end of 2026 and expanding at a CAGR of over 20% during the forecast period, 2019 to
Liquid biopsy tests are executed to understand the molecular aspects of cancer across
the healthcare and research settings, such as hospitals, physicians, pathological
and research laboratories.